[Use of omaron in patients with post-stroke cognitive disorders].
Efficacy of omaron (a combination of piracetam 400 mg and cinnarizin 25 mg) has been studied 3 months after stroke in 90 post-stroke patients. Forty-five patients receiving the basic therapy (antihypertensive and antithrombotic drugs, statins) have been included in the control group and 45 patients of the main group received in addition omaron (1 pill 3 times daily during 2 months). Intensity of neurologic disturbances, degree of disability, cognitive functions assessed by neuropsychological tests (the Mini-Mental State Examination, the Frontal Assessment battery, the Five words test, the Clock drawing test, the Schulte test) and emotional state (the Centre for Epidemiologic Studies Depression scale, the Spilberger scale) have been measured. During the period of the study, none of the patients had stroke or myocardial infarction. The improvement of indices of neurological status, decrease of disability degree and normalization of arterial pressure were found in both groups after 2 months of treatment. The significant improvement (p<0,05) of performance on tests for neurocognitive functions and parameters of emotional state was noted in patients treated with omaron compared to those of the control group. The good tolerability of omaron, absence of serious side-effect in combination with other drugs used for prevention of secondary stroke were reported.
Parfenov
V A
VA
Belavina
G R
GR
Vakhnina
N V
NV
Gusev
V V
VV
Levin
Ia I
IaI
Markin
S P
SP
Starchina
Iu A
IuA
D000284:Administration, Oral; D000368:Aged; D002936:Cinnarizine / Q000008:administration & dosage / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use*; D020521:Stroke / Q000150:complications*; D016896:Treatment Outcome
D004338:Drug Combinations; D006634:Histamine H1 Antagonists; D018696:Neuroprotective Agents; D002936:Cinnarizine; D010889:Piracetam